Evidence map›Paper›PMID 39961939›Full record

ArticleJournal of neuro-oncology2025

Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.

Leire Balaguer-Lluna, Nagore G Olaciregui, Rosario Aschero, Claudia Resa-Pares, Sonia Paco, Maria Cuadrado-Vilanova, Victor Burgueño, Merce Baulenas-Farres, Carles Monterrubio, Alejandro Manzanares and 4 more

Abstract read
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Leire Balaguer-LlunaPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Nagore G OlacireguiPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Rosario AscheroPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Claudia Resa-ParesPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Sonia PacoPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Maria Cuadrado-VilanovaPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Victor BurgueñoPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Merce Baulenas-FarresPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Carles MonterrubioPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Alejandro ManzanaresPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Eva RodríguezPathology, Hospital Sant Joan de Deu, Barcelona, 08950, Spain.
Cinzia LavarinoPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Jaume MoraPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain.
Angel M CarcabosoPediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain. angel.montero@sjd.es.

Funding

FP7 People: Marie-Curie Actions PIRG-08-GA-2010-276998Fundació la Marató de TV3 201927-30-31Instituto de Salud Carlos III CP13/00189Instituto de Salud Carlos III FI22/00160
6 · The paper itself

Abstract

purposeWe aimed to expand and refine the experimental models for pediatric-type diffuse high grade gliomas (pHGG) and the methods to follow up disease progression in mouse pHGG xenografts.

methodsUsing whole exome sequencing and immunoassays we characterized pHGG primary cultures and xenografts established at hospital SJD Barcelona. We obtained tumor samples and serial CSF samples from mouse xenografts. To assess tumor progression, we evaluated: (1) mouse weight, (2) human cell counts in brain paraffin sections, and (3) tumor DNA amount, quantified through droplet digital polymerase chain reaction (ddPCR) in paraffin sections and cerebrospinal fluid (CSF).

resultsWe established 15 experimental models of three pHGG subclasses, four of which engrafted in mice. Xenografts HSJD-DIPG-007 and HSJD-DMG-005 are diffuse midline glioma (DMG) H3 K27-altered, HSJD-GBM-002 is an H3 G34-mutant diffuse hemispheric glioma, and HSJD-GBM-001 is an H3-wildtype and IDH-wildtype pHGG. ddPCR quantification of human H3F3A K27M, H3F3A G34R, and ACVR1 R206H in paraffin samples is linear and sufficiently sensitive. We required a preamplification step to detect H3F3A K27M in CSF. In HSJD-DIPG-007 xenografts, human cell counts correlated with H3F3A amounts in paraffin for the whole engraftment period. Weight loss correlated with human cell counts and H3F3A amounts in paraffin. Serial collection of CSF was feasible, but H3F3A amounts in the CSF correlated only with weight loss.

conclusionThe developed methods contribute to the preclinical field of pHGG and introduce for the first time the concept of liquid biopsy in mice, which still needs improvement regarding its use as a preclinical biomarker.

Indexed as

Brain NeoplasmsDisease Models, AnimalGliomaTumor BurdenAnimalsChildFemaleHeterograftsHistonesHumansMaleMiceNeoplasm GradingHistonesDiffuse hemispheric glioma H3 G34-mutantDiffuse midline gliomas (DMG)Diffuse pediatric-type high-grade glioma H3-wildtype and IDH-wildtypeMouse xenograftsPediatric-type diffuse high-grade gliomas (pHGG)

Identifiers

PMID39961939
PMCPMC11968510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.